The FDA’s Alzheimer’s betrayal ...Middle East

NY Daily News - Opinion
On June 7, the Food and Drug Administration (FDA) approved a new drug from Biogen — Aduhelm — for the treatment of Alzheimer’s Disease after a gap of approximately 20 years since the last drug was approved to treat this terrible condition. The drug is an antibody that binds to the protein beta-amyloid, which is a biomarker of the disease. The approval was largely based on the ability of the drug to lower beta-amyloid levels in the brain, even though this phenomenon was not associated with discernible clinical improvement and early results were conflicting.

Hence then, the article about the fda s alzheimer s betrayal was published today ( ) and is available on NY Daily News ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( The FDA’s Alzheimer’s betrayal )

Apple Storegoogle play

Last updated :

Also on site :